TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25347448
Drug: Oral anti-psychotic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-psychotic therapy (retrospective)
Study: 25348520
Drug: Faldaprevir (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir (480 mg)
Study: 25348609
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg elemental zinc, oral zinc acetate, twice daily for 14 days)
Study: 25349968
Drug: Pazopanib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (oral angiogenesis inhibitor targeting VEGFR/PDGFR/c-Kit)
Study: 25351198
Drug: IK-5001 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IK-5001 (2 ml of 1% sodium alginate plus 0.3% calcium gluconate) administered by selective injection through the infarct-related coronary artery within 7 days after myocardial infarction
Study: 25352936
Drug: Efavirenz monotherapy
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz monotherapy (600 mg single dose and 600 mg/d for 17 days)
Study: 25355245
Drug: Oral lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide at a dose of 25 mg daily on days 1 to 21 of each 28-day cycle
Study: 25355284
Drug: 160-mg subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24
Study: 25355819
Drug: Ibrutinib (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (280 or 560 mg) combined with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2))
Study: 25355844
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg efavirenz daily
Study: 25357043
Drug: AeroForm patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: AeroForm patient-controlled tissue expanders; 10-cc dose of carbon dioxide gas administered three times daily with a 3-hour lockout until full expansion achieved.
Study: 25358826
Drug: Phosphodiesterase type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase type 5 inhibitors (PDE5i)
Study: 25358826
Drug: Weekly use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly use of PDE5i
Study: 25359291
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and adalimumab treatment
Study: 25359642
Drug: Monitoring (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring (oral hygiene instruction, applying or prescribing fluoride or varnish, or both)
Study: 25359988
Drug: Rituximab and
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and chemotherapy (6 5-day cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy; Rituximab given before each cycle and twice as maintenance, total of 8 doses)
Study: 25359988
Drug: Rituximab and
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and chemotherapy
Study: 25359994
Drug: Cytokine pathway
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine pathway treatment targeting STAT3
Study: 25360888
Drug: 14 SNPs
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 SNPs previously suggested to influence aspirin efficacy
Study: 25361625
Drug: Thalidomide (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (starting dose 200 mg/day, escalated to a maximum of 1,000 mg/day) combined with TACE
Study: 25361837
Drug: Individualised DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised DAPT guided by MEA (treatment for HPR to ADP with prasugrel or ticagrelor, clopidogrel reloading)
Study: 25362970
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily until progression or unacceptable toxicities
Study: 25363606
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg once daily for 4 weeks
Study: 25363606
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg added to tamsulosin after 4 weeks for patients with residual symptoms
Study: 25363606
Drug: Predictive factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive factors for solifenacin add-on therapy
Study: 25363997
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT) of warfarin, aspirin, and clopidogrel
Study: 25363997
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (DT) of warfarin and single antiplatelet agent (aspirin or clopidogrel)
Study: 25363997
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy (DAPT) of aspirin and clopidogrel
Study: 25366688
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m², once every 3 weeks)
Study: 25366688
Drug: No DTCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No DTCs after treatment with docetaxel
Study: 25369108
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg, subcutaneously every 4 weeks for 6 months
Study: 25369558
Drug: Paired daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) in collaborative units.
Study: 25369725
Drug: Cognitive-behavioral therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapies tailored to caregiver thinking patterns
Study: 27899756
Drug: NOAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC treatment
Study: 25372029
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) with SP and SP-PQ
Study: 25373390
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages sent as an adjunct to group Cognitive Behavioral Therapy (CBT) for depression.
Study: 25374341
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg orally twice daily until disease progression or drug intolerance
Study: 25374386
Drug: Antithrombotic agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic agents initiated in the prehospital phase
Study: 25374386
Drug: Any GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any GP IIb/IIIa inhibitor
Study: 25374386
Drug: Dual combination
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combination of ASA+(clopidogrel/prasugrel)
Study: 25374386
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of five drug classes (ASA, P2Y12 antagonists, statin, beta blocker, ACE-I/ARB)
Study: 25376618
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR (60 mg every 4 weeks)
Study: 25377157
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral panobinostat (single dose)
Study: 25377157
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral panobinostat (thrice weekly)
Study: 25377177
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard mycobacterial growth indicator tube (MGIT) drug susceptibility tests
Study: 25377187
Drug: Prophylactic infusions
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusions of FXIII concentrate (human) 40 IU kg(-1) every 4 weeks for 12 months
Study: 25377187
Drug: Prophylactic infusions
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusions of FXIII concentrate (human)
Study: 25380183
Drug: LGX818 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGX818 (300 mg daily)
Study: 25380636
Drug: Farletuzumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farletuzumab (administered by intravenous injection, dose escalation planned in 4 cohorts: 50, 100, 200, and 400 mg/m(2))
Study: 25380654
Drug: L-H status
Normalized name: Belagenpumatucel-L (NCI H-520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-H status (combined Lauren classification and HER2 status)
Study: 25380654
Drug: L-H status
Normalized name: Belagenpumatucel-L (NCI H-520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-H status vs Lauren classification
Study: 25381131
Drug: Vosaroxin (80-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosaroxin (80-90 mg/m²) plus cytarabine (schedule A: 400 mg/m²/day, days 1-5; schedule B: 1 g/m²/day, days 1-5)
Study: 25382351
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial therapy (IT)
Study: 25384705
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion irradiation, median dose 36 Gy (RBE), range 36-51 Gy (RBE)
Study: 25385094
Drug: Faldaprevir (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with methadone
Study: 25385094
Drug: Faldaprevir (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with buprenorphine-naloxone
Study: 25385099
Drug: Ethinylestradiol (EE)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol (EE) and Levonorgestrel (LNG) coadministered with 240 mg faldaprevir QD
Study: 25385409
Drug: Hyperglycaemia (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (plasma glucose 16 mmol/l)
Study: 25386899
Drug: Minimal Intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Intervention Group (MIG) - goal to increase child's activity to 6000 pedometer steps/day above baseline, daily monitoring by parents
Study: 25387993
Drug: Septal reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septal reduction therapy (septal myectomy or alcohol septal ablation)
Study: 25387993
Drug: Endoscopic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic intervention and medical therapy for hypertrophic cardiomyopathy
Study: 25388099
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections, administered in cycles of two injections 24-72 hours apart, repeated after 6 weeks for ≤4 cycles.
Study: 25388099
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections.
Study: 25388167
Drug: PF-04449913 640
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 640 mg once daily
Study: 25388167
Drug: PF-04449913 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 320 mg once daily
Study: 25388167
Drug: PF-04449913 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 80 to 320 mg once daily
Study: 25389254
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination for HCWs with anti-HBs <12 mIU/mL
Study: 25389443
Drug: Zembrin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zembrin 25 mg daily for 3 weeks
Study: 25392936
Drug: Hyperfiltering adolescents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfiltering adolescents with T1D (GFR ≥ 135 ml/min/1.73 m²)
Study: 25392936
Drug: Normofiltering adolescents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normofiltering adolescents with T1D (GFR < 135 ml/min/1.73 m²)
Study: 25393520
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (n = 118)
Study: 25393520
Drug: Daily therapy
Normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily therapy (n = 99)
Study: 25393536
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d omega-3 acid ethyl esters (P-OM3) for 8 weeks
Study: 25393640
Drug: Liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6 mg/d for 2 weeks, followed by 1.2 mg/d) in addition to metformin (1500 mg/d)
Study: 25393648
Drug: Vorinostat 400
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 400 mg orally once daily for 14 days
Study: 25394029
Drug: Maraviroc (MVC)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc (MVC) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs)
Study: 25394093
Drug: LPV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r monotherapy OD (LPVrMOD)
Study: 25394116
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell count increase during treatment
Study: 25394136
Drug: Immunoglobulin at
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin at birth and complete vaccine schedule during the first six months of life
Study: 25394136
Drug: Immunoglobulin and
Normalized name: Immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279) and HAVCR2 (hepatitis A virus cellular receptor 2, T cell immunoglobulin and mucin domains family member 3, TIM3, TIM-3, TIMD3, CD366)], humanized and Ho
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin and complete vaccine schedule
Study: 25395260
Drug: Kidney transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney transplantation from HBsAg(+) donors with lamivudine in combination with HBV immunoglobulin
Study: 25395425
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy plus IFRT
Study: 25395429
Drug: Dinaciclib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib at 30 mg/m²
Study: 25395429
Drug: Dinaciclib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib at 40 mg/m²
Study: 25395429
Drug: Dinaciclib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib at 50 mg/m²
Study: 25396060
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (25(OH)D levels <20 ng/mL)
Study: 25397516
Drug: DRV/COBI 800/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/COBI 800/150 mg qd plus two fully active N[t]RTIs
Study: 25397527
Drug: etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine (ETR) 200 mg bid with an optimised background regimen (BR) excluding DRV/r or NRTIs only
Study: 25398082
Drug: Training of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training of unlicensed healthcare providers in zinc treatment and diarrhoea management
Study: 25399249
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy with adaptive difficulty levels
Study: 25399779
Drug: Levosimendan (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (administered immediately after anaesthesia induction)
Study: 25399779
Drug: Levosimendan (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (administered later after postoperative ICU admission)
Study: 25400468
Drug: Neoadjuvant continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy followed by laparoscopic mesorectal excision.
Study: 25400468
Drug: Withholding adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision.
Study: 25402221
Drug: Deferasirox 30
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox 30 mg/kg/d
Study: 25402488
Drug: (131)I-CLR1404, 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I-CLR1404, 370 MBq single injection
Study: 25402488
Drug: (131)I-CLR1404, 740
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I-CLR1404, 740 MBq predicted administration
Study: 25403209
Drug: 3.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Study: 25403209
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Study: 25403209
Drug: 0.3 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Study: 25403209
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-15 (rhIL-15) administration
Study: 25403217
Drug: Atu027 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atu027 (10 escalating doses, 0.336 mg/kg, intravenous infusions twice per week during a 28-day cycle)
Study: 25403830
Drug: vosaroxin 72
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vosaroxin 72 mg/m² d 1, 4
Study: 25403830
Drug: vosaroxin 72
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vosaroxin 72 mg/m² d 1, 8, 15
Study: 25403830
Drug: vosaroxin 72
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vosaroxin 72 mg/m² d 1, 8
Study: 25403830
Drug: vosaroxin 90
Normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vosaroxin 90 mg/m² d 1, 4
Study: 25404094
Drug: Belinostat (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat (1000 mg/m² intravenously ×5 days of a 21-day cycle)
Study: 25404412
Drug: QuantiFERON(®)-TB GOLD
Normalized name: QUANTIFERON-TB GOLD
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuantiFERON(®)-TB GOLD (QFT-G)
Study: 25404952
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of LY2811376
Study: 25404952
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of LY2811376
Study: 25405351
Drug: Baminercept (lymphotoxin-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baminercept (lymphotoxin-beta receptor-immunoglobulin fusion protein)
Study: 25405614
Drug: 14-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day antibiotic therapy during acute exacerbations
Study: 25405724
Drug: Chloroquine by
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine by directly observed therapy
Study: 25405724
Drug: Antibody response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibody response to merozoite surface protein 1 (MSP-1)
Study: 25408112
Drug: Angiopoietin-2 concentrations
Normalized name: Immunoglobulin G1 Fab fragment, bispecific, anti-(human vascular endothelial growth factor A and angiopoietin 2) (human monoclonal RO7250284 γ1-chain), disulfide with human monoclonal RO7250284 κ-chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiopoietin-2 concentrations at discharge above 2,500 pg/ml
Study: 25408662
Drug: lanreotide Autogel(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections
Study: 25408662
Drug: octreotide long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide long-acting release (LAR) 30 mg monthly
Study: 25408662
Drug: chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy treatment with cisplatinum-etoposide
Study: 25409372
Drug: AAV8 vector
Normalized name: Recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase
DrugBank: Avalotcagene ontaparvovec (DB16796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8 vector gene therapy (high dose: 2×10(12) vector genomes per kg)
Study: 25409372
Drug: AAV8 vector
Normalized name: Recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase
DrugBank: Avalotcagene ontaparvovec (DB16796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8 vector gene therapy (high dose)
Study: 25409372
Drug: AAV8 vector
Normalized name: Recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase
DrugBank: Avalotcagene ontaparvovec (DB16796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8 vector gene therapy
Study: 25411597
Drug: Ipragliflozin 25
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 25 mg
Study: 25413133
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of NO and oxygen
Study: 25415228
Drug: MCT1/2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT1/2 inhibitor (AR-C155858)
Study: 25415228
Drug: Oligomycin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligomycin A (inhibitor of mitochondrial ATP synthase)
Study: 25416418
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care providers' awareness of treatment burden